JP2007523215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523215A5 JP2007523215A5 JP2007500925A JP2007500925A JP2007523215A5 JP 2007523215 A5 JP2007523215 A5 JP 2007523215A5 JP 2007500925 A JP2007500925 A JP 2007500925A JP 2007500925 A JP2007500925 A JP 2007500925A JP 2007523215 A5 JP2007523215 A5 JP 2007523215A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- use according
- lapachone
- phase drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims 66
- 150000003839 salts Chemical class 0.000 claims 62
- 230000018199 S phase Effects 0.000 claims 47
- 229940079593 drug Drugs 0.000 claims 44
- 239000003814 drug Substances 0.000 claims 44
- 229960005277 gemcitabine Drugs 0.000 claims 22
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000003937 drug carrier Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000002207 metabolite Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 8
- 229960002949 fluorouracil Drugs 0.000 claims 8
- 229960000485 methotrexate Drugs 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 230000000340 anti-metabolite Effects 0.000 claims 4
- 229940100197 antimetabolite Drugs 0.000 claims 4
- 239000002256 antimetabolite Substances 0.000 claims 4
- 229960002756 azacitidine Drugs 0.000 claims 4
- 229960002170 azathioprine Drugs 0.000 claims 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 4
- 229960002436 cladribine Drugs 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 4
- 229960000961 floxuridine Drugs 0.000 claims 4
- 229960000390 fludarabine Drugs 0.000 claims 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 4
- 229960001428 mercaptopurine Drugs 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229960003087 tioguanine Drugs 0.000 claims 4
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000030833 cell death Effects 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 229940127073 nucleoside analogue Drugs 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54728704P | 2004-02-23 | 2004-02-23 | |
| US11/068,459 US20050197406A1 (en) | 1999-04-14 | 2005-02-18 | Method of treatment of lung cancer |
| US11/060,747 US20050192360A1 (en) | 1999-04-14 | 2005-02-18 | Method of treatment of pancreatic cancer |
| PCT/US2005/005620 WO2005082354A1 (en) | 2004-02-23 | 2005-02-23 | Beta-lapachone and s-phase drug combinations for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523215A JP2007523215A (ja) | 2007-08-16 |
| JP2007523215A5 true JP2007523215A5 (enExample) | 2008-03-27 |
Family
ID=34916185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500925A Withdrawn JP2007523215A (ja) | 2004-02-23 | 2005-02-23 | 癌治療のためのβ−ラパコンおよびＳ期薬組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1727536A1 (enExample) |
| JP (1) | JP2007523215A (enExample) |
| CA (1) | CA2556759A1 (enExample) |
| WO (1) | WO2005082354A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| WO2005082359A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
| KR101752697B1 (ko) * | 2015-04-17 | 2017-07-03 | (주)나디안바이오 | 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물 |
| CN110478363B (zh) * | 2019-08-22 | 2022-09-06 | 北京大学 | cIMP的药物新用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1387677A2 (en) * | 2000-11-07 | 2004-02-11 | Dana-Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers using beta lapachone |
| WO2002056823A2 (en) * | 2001-01-18 | 2002-07-25 | Arnold Hoffman | Redox therapy for tumors |
| JP2005538981A (ja) * | 2002-07-17 | 2005-12-22 | アーキュル， インコーポレイテッド | 活性化チェックポイント療法およびこれらの使用方法 |
-
2005
- 2005-02-23 JP JP2007500925A patent/JP2007523215A/ja not_active Withdrawn
- 2005-02-23 WO PCT/US2005/005620 patent/WO2005082354A1/en not_active Ceased
- 2005-02-23 CA CA002556759A patent/CA2556759A1/en not_active Abandoned
- 2005-02-23 EP EP05713938A patent/EP1727536A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lü et al. | Homoharringtonine and omacetaxine for myeloid hematological malignancies | |
| Noble et al. | Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer | |
| ES2964764T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino | |
| JP2012521435A5 (enExample) | ||
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| JP2022180461A5 (enExample) | ||
| JP2006504745A5 (enExample) | ||
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| NZ602833A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| JP2005537268A5 (enExample) | ||
| ME02395B (me) | Kombinovana terapija sa antitumorskim alkaloidima | |
| JP2006504723A5 (enExample) | ||
| JP2019530660A (ja) | ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法 | |
| JP2010525042A5 (enExample) | ||
| US10342817B2 (en) | Combination therapy using ribavirin as elF4E inhibitor | |
| US20130196938A1 (en) | Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| Mornex et al. | Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art | |
| JP2006514681A5 (enExample) | ||
| JP2007523215A5 (enExample) | ||
| JP2006503095A5 (enExample) | ||
| CN101355969B (zh) | 包含cyc-682和细胞毒性药物的抗增殖性组合 | |
| Giles et al. | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase | |
| JP2011500650A5 (enExample) | ||
| JP2011513315A5 (enExample) | ||
| RU2002133963A (ru) | Комбинированная химиотерапия |